Last reviewed · How we verify
Penicillin versus cefuroxim per os
Penicillin and cefuroxim per os are marketed antibiotics, with a key composition patent expiring in 2028. The key strength lies in their well-established use and broad spectrum of activity against common bacterial infections. The primary risk is the increasing prevalence of antibiotic resistance, which may limit their effectiveness over time.
At a glance
| Generic name | Penicillin versus cefuroxim per os |
|---|---|
| Sponsor | University Children's Hospital Basel |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis. (NA)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Conservative Versus Operative ManageMent of Acute Uncomplicated Appendicitis (NA)
- Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Streptococcal Dermatitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: